CLDN6 recombinant proteins and antibodies

Tight junction protein 6 (CLDN6) is a member of the tight junction protein (Claudins, CLDNs) family. Claudins are mainly expressed in endothelial cells or epithelial cells in a tissue-specific manner. According to the degree of sequence homology of different claudins, these members can be divided into two categories, namely classical and non-classical claudins. CLDN6 belongs to the classical claudins, which has the function of tight junction permeability regulation and barrier formation. Unlike other claudin members, CLDN6 is the only CLDN with potential specificity because it can activate cell adhesion signals and regulate the activity of nuclear receptors. CLDN6 can be regulated by stimulation and transcription factors, DNA methylation, phosphorylation and palmitoylation. As the main structure of tight junctions, abnormal expression of Claudins can lead to structural destruction and functional impairment of epithelial cells and endothelial cells, and it is abnormally expressed in a variety of epithelial tumors. For example, the expression of Cliaudin2 in prostate cancer and breast cancer, Claudin3 in renal cancer and bladder cancer, and Claudin4 in renal cancer and liver cancer are all downregulated. Unlike other CLDNs, CLDN6 is a tumor-specific protein that is present in a variety of solid tumors, including ovarian, endometrial, lung, stomach, and testicular, but not in healthy adult tissues. Based on this, in recent years, more and more studies have been conducted on the role of CLDN6 in cancer. As research results continue to be disclosed, CLDN6 has gradually become an ideal target for tumor treatment. More about the mechanism of action of CLDN6 >>

However, since CLDN6 is closely related to Claudins such as CLDN3, CLDN4, and CLDN9, and there is genetic overlap, the development of CLDN6 targeted therapeutic drugs has come to a standstill, and the high selectivity of drugs for CLDN6 has become a key breakthrough in the development of CLDN6 targeted therapeutic drugs.

DIMA BIOTECH used its innovative Nanodisc full-length membrane protein preparation platform and combined it with the advantages of mammalian cell expression to successfully express the biologically active full-length CLDN6 membrane protein. In addition, for the CLDN6 target, DIMA BIOTECH also provides a variety of active ECD proteins, flow cytometry-verified monoclonal antibodies, reference antibodies, and stable cell lines. Moreover, in order to accelerate the development of CLDN6 target drugs, DIMA BIOTECH also prepared a B cell seed bank for CLDN6, which can complete the screening of lead antibody molecules in as fast as 20 days.